<DOC>
	<DOCNO>NCT01345669</DOCNO>
	<brief_summary>This randomise , double-blind phase III trial perform patient head neck squamous cell carcinoma ( HNSCC ) . The objective trial compare efficacy safety afatinib ( BIBW 2992 ) placebo adjuvant therapy patient receive definitive chemo-radiotherapy .</brief_summary>
	<brief_title>LUX-Head &amp; Neck 2 : A Phase III Trial Afatinib ( BIBW 2992 ) Versus Placebo Treatment Head Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologically cytologically confirm locoregionally advanced head neck squamous cell carcinoma ( HNSCC ) , stage III IVb 2 . Unresected tumour prior chemoradiotherapy ( CRT ) 3 . Concomitant CRT complete prior randomisation 4 . After concomitant platinumbased CRT , evidence disease ( NED ) clinical radiographic examination 5 . Eastern cooperative oncology group ( ECOG ) performance status 0 1 Exclusion criterion : 1 . Prior treatment epidermal growth factor receptor ( EGFR ) target small molecule , EGFRtargeted antibody , and/or investigational agent HNSCC 2 . Patients smoke history less equal 10 pack year primary tumour site base tongue and/or tonsil 3 . Any malignancy ( except simultaneous HNSCC primary , appropriately treat superficial basal cell skin cancer surgically cure cervical cancer situ ) unless free disease least five year 4 . Known preexist Interstitial Lung Disease ( ILD ) 5 . Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>